Last edition
News about "FDA drug review"
US FDA Accepts EIT Pharma's Lonafarnib NDA for Treating Chronic Hepatitis D
EIT Pharma’s lonafarnib New Drug Application (NDA) has been accepted by the US Food and Drug Administration (FDA) for chronic hepatitis D, marking a key step toward a potential first oral treatment option.
FDA Drug Review | 13/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members